Ulcer Treatment Patents (Class 514/925)
  • Patent number: 9493457
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 15, 2016
    Assignee: Proximagen Limited
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • Patent number: 8912165
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: December 16, 2014
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Patent number: 8632823
    Abstract: Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has a redox potential of >950 mV. Medicaments based on the super-oxidized water may be in liquid or gel form. The super-oxidized water is able to control the microbial population within the wound and at the same time permit cell proliferation.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: January 21, 2014
    Assignee: Puricore, Inc.
    Inventor: Joe B. Selkon
  • Patent number: 8501710
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages as active ingredients.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: August 6, 2013
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Patent number: 8455549
    Abstract: The present invention relates to the use of a particular group of carbonylamino derivatives for the treatment or alleviation of a disease or condition relating to certain inflammatory disorders.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: June 4, 2013
    Assignee: Aniona Aps
    Inventors: Lars Siim Madsen, Palle Christophersen
  • Patent number: 8415159
    Abstract: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 9, 2013
    Assignee: Mesynthes Ltd.
    Inventors: Brian Roderick Ward, Keryn Dallas Johnson, Barnaby Charles Hough May
  • Patent number: 8383690
    Abstract: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 26, 2013
    Assignee: Council of Scientific and Industrial Research
    Inventors: Sukdeb Banerjee, Pratap K. Das, Suchandra Goswami, Annalakshmi Chinniah, Nilendu Panda, Niranjan Prasad Sahu, Basudeb Achari
  • Patent number: 8372429
    Abstract: An agent for treating ulcer containing, as an effective component, a particulate composite hydrotalcite obtained by solidly dissolving a small amount of zinc in the particulate hydrotalcite, exhibiting excellent effect for treating the peptic ulcer and, further, working as a Zn-supplying agent. The agent for treating the ulcer is represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.1?a<1, 0<b?0.5, 0?m<1.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: February 12, 2013
    Assignee: Kyowa Chemical Industry Co., Ltd.
    Inventors: Keiko Katsuki, Akira Okada
  • Patent number: 8216608
    Abstract: A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.5?a<1, 0<b?0.5, 0?m<1, and a gastric antacid using the particulate composite hydrotalcite as an effective component. When used as a gastric antacid, the particulate composite hydrotalcite suppresses the occurrence of damage in the mucous membranes of stomach and intestines.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: July 10, 2012
    Assignee: Kyowa Chemical Industry Co., Ltd.
    Inventors: Akira Okada, Keiko Katsuki
  • Patent number: 8187614
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 29, 2012
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7956047
    Abstract: The present invention comprises the use of chondroitin sulphate (CS-E) or an active fragment thereof for the treatment of diseases or conditions related to collagen fibril formation. Said compounds can be administrated either by oral, topical, injectable or by any other suitable route.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: June 7, 2011
    Assignee: AnaMar AB
    Inventors: Anders Aspberg, Dick Heinegård, Anna Johnson, Alexander Kvist
  • Patent number: 7790672
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: September 7, 2010
    Assignee: Legere Pharmaceuticals, Inc.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7648968
    Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of dermal ulcers. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: January 19, 2010
    Assignee: Novogen Research Pty. Ltd.
    Inventor: Graham Edmund Kelly
  • Patent number: 7544710
    Abstract: The present invention relates to the use of the distrontium salt of 2-[N,N-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylic acid in obtaining medicaments intended for the treatment of gastro-duodenal pain.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: June 9, 2009
    Assignee: Les Laboratoires Servier
    Inventor: Yannis Tsouderos
  • Patent number: 7501135
    Abstract: A method of reducing gastric acid secretion in animals including humans comprising administering an extract of a plant of the genus Hoodia or Trichocaulon to animals, generally mammals.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: March 10, 2009
    Assignee: Conopco, Inc.
    Inventors: John Hakkinen, Roelof Marthinus Horak, Vinesh Maharaj
  • Patent number: 7371889
    Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.
    Type: Grant
    Filed: March 11, 2007
    Date of Patent: May 13, 2008
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
  • Patent number: 7291353
    Abstract: A pharmaceutical composition comprising an effective amount of an extract or lyophilized extract or at least one bioactive fraction obtained from the plant Woodfordia fruticosa along with one or more pharmaceutically acceptable additives/carriers for treating ulcer caused by the conditions such as stress induced ulcer, peptic ulcer, cold restraint induced ulcer, drug induced ulcer and acid induced ulcer, also used as specific inhibitor of gastric H+, K+-ATPase and anti-Helicobacter pylori activity.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: November 6, 2007
    Assignee: Council of Scientific and Industrial Research
    Inventors: Pratap K. Das, Niranjan P. Sahu, Sukdeb Banerjee, Suchandra Sett, Suchandra Goswami, Samir Bhattacharya
  • Patent number: 7276255
    Abstract: Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has a redox potential of >950 mV. Medicaments based on the super-oxidized water may be in liquid or gel form. The super-oxidized water is able to control the microbial population within the wound and at the same time permit cell proliferation.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: October 2, 2007
    Assignee: Sterilox Medical (Europe) Limited
    Inventor: Joe B. Selkon
  • Patent number: 7220418
    Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of said transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: May 22, 2007
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie
    Inventors: Wolfgang Christian Hans, Lothar Steidler, Erik René Remaut
  • Patent number: 7135197
    Abstract: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: November 14, 2006
    Assignee: Pharmacia Corporation
    Inventors: Lorraine E. Pena, Dennis L. Huczek
  • Patent number: 7097860
    Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 29, 2006
    Inventors: Aaron Moshenyat, Anna Moshenyat, Reuven Moshenyat, Yitzchak Moshenyat
  • Patent number: 7087249
    Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 8, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
  • Patent number: 7041316
    Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: May 9, 2006
    Assignee: Sage Pharmaceuticals, Inc.
    Inventor: Jivn-Ren Chen
  • Patent number: 7034060
    Abstract: The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela. Included in the present invention is the composition of matter, referred to herein as “polycosanol” produced by the method of this invention. The polycosanol composition is comprised primarily of the four primary aliphatic alcohols, tetracosanol, hexacosanol, octacosanol and triacontanol. Further included in this invention is the use of said composition of matter for the prevention and treatment of obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: April 25, 2006
    Assignee: Unigen Pharmaceuticals, Inc.
    Inventors: Qi Jia, Ji-Fu Zhao
  • Patent number: 6984666
    Abstract: The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela. Included in the present invention is the composition of matter, referred to herein as “polycosanol” produced by the method of this invention. The polycosanol composition is comprised primarily of the four primary aliphatic alcohols, tetracosanol, hexacosanol, octacosanol and triacontanol. Further included in this invention is the use of said composition of matter for the prevention and treatment of obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: January 10, 2006
    Assignee: Unigen Pharmaceuticals, Inc.
    Inventors: Qi Jia, Ji-Fu Zhao
  • Patent number: 6958159
    Abstract: The present invention relates to an improved pharmaceutical composition useful for the topical treatment of burns, cuts, wounds, abrasions and the like, and to methods of treatment of injured body surfaces such as skin.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: October 25, 2005
    Assignee: Chiltern Pharmaceuticals, Pty Ltd.
    Inventor: Robert Alan Smith
  • Patent number: 6869927
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: March 22, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Patent number: 6863904
    Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: March 8, 2005
    Assignee: Everett Laboratories, Inc.
    Inventors: John A. Giordano, Charles Balzer
  • Patent number: 6855347
    Abstract: The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, a method for preparing said synergistic herbal composition and a process for the treatment of gastric ulcer using said composition and more particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: February 15, 2005
    Assignee: Council of Scientific and Industrial Research
    Inventors: Janaswamy Madhusudana Rao, Upparapalli Sampathkumar, Boggavarapu Subrahmanya Sastry, Jhillu Singh Yadav, Kondapuram Vijaya Raghavan, Gautam Palit, Deepak Rai, Panniyampally Madhavankutty Varier, Trikovil Sankaran Muraleedharan, Kollath Muraleedharan
  • Patent number: 6828313
    Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: December 7, 2004
    Assignee: Savient Pharmaceuticals, Inc.
    Inventor: Don Fishbein
  • Patent number: 6822004
    Abstract: The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela. Included in the present invention is the composition of matter, referred to herein as “polycosanol” produced by the method of this invention. The polycosanol composition is comprised primarily of the four primary aliphatic alcohols, tetracosanol, hexacosanol, octacosanol and triacontanol. Further included in this invention is the use of said composition of matter for the prevention and treatment of obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: November 23, 2004
    Assignee: UniGen Pharmaceuticals, Inc.
    Inventors: Qi Jia, Ji-Fu Zhao
  • Patent number: 6780881
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: August 24, 2004
    Assignee: Altana Pharma AG
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6767559
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6762170
    Abstract: There are provided according to the invention, novel compounds of formula (I) wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory disease.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: July 13, 2004
    Assignee: SmithKlineBeecham Corporation
    Inventors: Chuen Chan, Richard Charles Peter Cousins, Brian Cox
  • Patent number: 6726927
    Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: April 27, 2004
    Assignee: Sage Pharmaceuticals, Inc.
    Inventor: Jivn-Ren Chen
  • Patent number: 6703049
    Abstract: The present invention relates to a novel angiogenesis inhibitor, more particularly, arsenolite (solid As4O6) and composition containing the same. The arsenolite of the present invention inhibits endothelial cell proliferation and tube formation so that it can be used for medication of various angiogenic diseases.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: March 9, 2004
    Inventors: II Ju Bae, Kang Moon Seo, Chang Hun Rhee
  • Patent number: 6696486
    Abstract: The present invention relates to the use of compounds which act as agonists at atypical beta-adrenoceptors, for the treatment of gastrointestinal disorders, especially peptic ulceration, oesophagitis, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and gastrointestinal ulcerations, especially when induced by non-steroidal anti-inflammatory drugs or corticosteroids.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: February 24, 2004
    Assignee: Glaxo Group Limited
    Inventor: Ashwani Kumar Bahl
  • Patent number: 6683116
    Abstract: The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela. Included in the present invention is the composition of matter, referred to herein as “polycosanol” produced by the method of this invention. The polycosanol composition is comprised primarily of the four primary aliphatic alcohols, tetracosanol, hexacosanol, octacosanol and triacontanol. Further included in this invention is the use of said composition of matter for the prevention and treatment of obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: January 27, 2004
    Assignee: Unigen Pharmaceuticals, Inc.
    Inventors: Qi Jia, Ji-Fu Zhao
  • Patent number: 6669966
    Abstract: Skin-growth-enhancing compounds and compositions including a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and Ag(I,III) oxide, or a combination thereof. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. Also included are articles containing such compositions, such as wound dressings, and methods for facilitating or enhancing skin growth using these compounds, compositions, and articles, such as for the treatment or management of burns or skin grafts.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: December 30, 2003
    Assignee: Marantech Holding LLC
    Inventor: Marvin S. Antelman
  • Patent number: 6645978
    Abstract: Ophthalmic compositions containing Lipoxin A4 and its analogs and methods of their use for treating dry eve are disclosed.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: November 11, 2003
    Assignee: Alcon, Inc.
    Inventors: Daniel A. Gamache, Gustav Graff, Mark R. Hellberg, Peter G. Klimko, John M. Yanni
  • Patent number: 6638523
    Abstract: A method of treating ulcers comprising administering an effective amount of carnosic acid and/or carnosol or a plant extract containing carnosic acid and/or carnosol as an effective ingredient to a subject having such ulcers.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: October 28, 2003
    Assignee: Nagase & Company, Ltd.
    Inventors: Toshitsugu Miyazaki, Kunio Kosaka, Hisatomi Ito
  • Patent number: 6610673
    Abstract: A swallowable, solid dose form composition for treating upper gastrointestinal tract distress containing bismuth subsalicylate, carbonate or bicarbonate salt, disintegrating agent, anionic or nonionic surfactant, and microcrystalline cellulose is described.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: August 26, 2003
    Assignee: The Procter & Gamble Company
    Inventors: Francis Bernard Chapura, Daniel Louis Barone, Michael Gerard Colacino
  • Patent number: 6593339
    Abstract: The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 15, 2003
    Assignee: AstraZeneca AB
    Inventors: Arne Eek, Johan Raud
  • Patent number: 6565895
    Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: May 20, 2003
    Assignee: GelTex Pharmaceuticals, Inc.
    Inventors: Philip J. Goddard, Jeffrey D. Klinger, Pradeep K. Dhal, W. Harry Mandeville, III, Richard J. Fitzpatrick, Thomas X. Neenan
  • Patent number: 6555534
    Abstract: The use of 4,4-methylenebis (tetrahydro-1,2-4-thiadiazine-1,1 -dioxide) in the eradication and control of the microorganism Helicobacter pylori in humans is disclosed.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 29, 2003
    Assignee: Medpointe Healthcare Inc.
    Inventor: James C. Costin
  • Patent number: 6555125
    Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions. The compositions of the present invention may also be combined with materials capable of forming seals over ulcers or lesions to further promote the healing process.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: April 29, 2003
    Inventor: Phillip Campbell
  • Patent number: 6545136
    Abstract: This invention relates to a process for producing a desulfated polysaccharide, which comprises reacting a sulfated polysaccharide having a saccharide in which a primary hydroxyl group is sulfated, as a constituent sugar, with a silylating agent represented by the following formula (I) wherein R1s are the same or different and each represent a hydrogen atom or a halogen atom, R2 represents a lower alkyl group, and R3s are the same or different and each represent a lower alkyl group, an aryl group or a halogen atom, and a desulfated heparin obtained by this production process.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: April 8, 2003
    Assignee: Seikagaku Corporation
    Inventors: Saburo Hara, Keiichi Yoshida, Masayuki Ishihara
  • Patent number: 6534486
    Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: March 18, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: David George Allen, Chuen Chan, Caroline Mary Cook, Richard Peter Charles Cousins, Brian Cox, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Stephen Swanson, Caroline Whitworth, David Bays
  • Patent number: 6528494
    Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 4, 2003
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
  • Patent number: 6518250
    Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: [wherein R1, R2, R3, and R4 independently denote a hydrogen atom or a lower alkyl group, R5 denotes a hydrogen atom, a lower alkyl group, or a lower acyl group, X denotes a monosaccharide residue or an oligosaccharide residue which may have a lower alkyl group or a lower acyl group substituted for the hydrogen atom of the hydroxyl group of the saccharide residue, n denotes an integer of 0-6, and m denotes an integer of 1-6]. The agent, even in a small dosage, acts safely and effectively on the affected part and allows the hindrances of ischemic reperfusion induced in heart, stomach, small intestine, liver, spleen, kidney, brain, and skin, and the hindrance induced during the transplantation of an internal organ to be prevented and cured.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: February 11, 2003
    Assignee: CCI Corporation
    Inventors: Toshikazu Yoshikawa, Hironobu Murase, Norimasa Yoshida